Saniona Vốn chủ sở hữu 2024

Saniona làm gì?

Saniona AB is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics for rare diseases. The company was previously known as Saniona AB (until 2014) and NeuroNova AB (until 2012). It was founded in Copenhagen, Denmark, in 2006 and quickly expanded to other countries. In 2013, the company opened an office in Boston, USA, to expand its activities in North America. Saniona AB is listed on the NASDAQ Stockholm and currently has over 60 employees worldwide. The company's business model revolves around discovering and developing drugs for rare diseases that have little to no existing therapies. They use a proprietary technology platform called Ion Channels and G Protein-Coupled Receptors (GPCRs) to identify novel compounds that could meet these urgent medical needs. Saniona AB aims to develop successful medications and sell them either through partnerships or their own marketing activities. The company operates in various areas, including rare diseases, the nervous system (developing drugs for movement disorders and psychiatric disorders), and diabetes and obesity. Saniona AB has several drug candidates in its pipeline targeting different therapeutic applications, with some in various stages of clinical development. One of its key products is Tesomet, a candidate for the treatment of Prader-Willi syndrome and hypothalamic-pituitary hormone disorders, which is currently in Phase 3 of clinical development. Another important candidate is AN788, being investigated in Phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis. In conclusion, Saniona AB is an emerging biopharmaceutical company developing innovative drugs for rare diseases. With a specialization in researching rare diseases with significant medical needs and unmet treatment options, the company utilizes a proprietary technology platform to identify new compounds that aim to fulfill these medical needs. With multiple drug candidates in development and a strong partnership strategy, Saniona is well-positioned to maximize the potential of its innovative therapies and benefit patients in need. Saniona ist eines der beliebtesten Unternehmen auf Eulerpool.com.